Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

MLA

Kim, Stephanie I., et al. “Correction: A Real-World Evaluation of Radium-223 in Combination with Abiraterone or Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer.” PloS One, vol. 16, no. 12, Dec. 2021, p. e0262326. EBSCOhost, https://doi.org/10.1371/journal.pone.0262326.

APA

Kim, S. I., Szeto, A. H., Morgan, K. P., Brower, B., Dunn, M. W., Khandani, A. H., Godley, P. A., Rose, T. L., Basch, E. M., Milowsky, M. I., Whang, Y. E., & Crona, D. J. (2021). Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PloS One, 16(12), e0262326. https://doi.org/10.1371/journal.pone.0262326

Chicago

Kim, Stephanie I, Andy H Szeto, Katherine P Morgan, Blaine Brower, Mary W Dunn, Amir H Khandani, Paul A Godley, et al. 2021. “Correction: A Real-World Evaluation of Radium-223 in Combination with Abiraterone or Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer.” PloS One 16 (12): e0262326. doi:10.1371/journal.pone.0262326.